

5-1-2017

## Fibulin-4 is essential for maintaining arterial wall integrity in conduit but not muscular arteries.

Carmen M. Halabi  
*Washington University School of Medicine*

Thomas J. Broekelmann  
*Washington University School of Medicine*

Michelle Lin  
*Washington University School of Medicine*

Vivian S. Lee  
*Washington University School of Medicine*

Follow this and additional works at: <https://jdc.jefferson.edu/dcbfp>

Mon-Li Chu

 Part of Jefferson University Biology Commons, and the Nephrology Commons

**[Let us know how access to this document benefits you](#)**

*See next page for additional authors*

### Recommended Citation

Halabi, Carmen M.; Broekelmann, Thomas J.; Lin, Michelle; Lee, Vivian S.; Chu, Mon-Li; and Mecham, Robert P., "Fibulin-4 is essential for maintaining arterial wall integrity in conduit but not muscular arteries." (2017). *Department of Dermatology and Cutaneous Biology Faculty Papers*. Paper 86.

<https://jdc.jefferson.edu/dcbfp/86>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Dermatology and Cutaneous Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).

---

**Authors**

Carmen M. Halabi, Thomas J. Broekelmann, Michelle Lin, Vivian S. Lee, Mon-Li Chu, and Robert P. Mecham

## VASCULAR PHYSIOLOGY

# Fibulin-4 is essential for maintaining arterial wall integrity in conduit but not muscular arteries

Carmen M. Halabi,<sup>1\*</sup> Thomas J. Broekelmann,<sup>2</sup> Michelle Lin,<sup>1</sup> Vivian S. Lee,<sup>2</sup> Mon-Li Chu,<sup>3</sup> Robert P. Mecham<sup>2</sup>

2017 © The Authors,  
some rights reserved;  
exclusive licensee  
American Association  
for the Advancement  
of Science. Distributed  
under a Creative  
Commons Attribution  
NonCommercial  
License 4.0 (CC BY-NC).

Homozygous or compound heterozygous mutations in fibulin-4 (*FBLN4*) lead to autosomal recessive cutis laxa type 1B (ARCL1B), a multisystem disorder characterized by significant cardiovascular abnormalities, including abnormal elastin assembly, arterial tortuosity, and aortic aneurysms. We sought to determine the consequences of a human disease-causing mutation in *FBLN4* (E57K) on the cardiovascular system and vascular elastic fibers in a mouse model of ARCL1B. *Fbln4*<sup>E57K/E57K</sup> mice were hypertensive and developed arterial elongation, tortuosity, and ascending aortic aneurysms. Smooth muscle cell organization within the arterial wall of large conducting vessels was abnormal, and elastic fibers were fragmented and had a moth-eaten appearance. In contrast, vessel wall structure and elastic fiber integrity were normal in resistance/muscular arteries (renal, mesenteric, and saphenous). Elastin cross-linking and total elastin content were unchanged in large or small arteries, whereas elastic fiber architecture was abnormal in large vessels. While the E57K mutation did not affect *Fbln4* mRNA levels, FBLN4 protein was lower in the ascending aorta of mutant animals compared to wild-type arteries but equivalent in mesenteric arteries. We found a differential role of FBLN4 in elastic fiber assembly, where it functions mainly in large conduit arteries. These results suggest that elastin assembly has different requirements depending on vessel type. Normal levels of elastin cross-links in mutant tissue call into question FBLN4's suggested role in mediating lysyl oxidase–elastin interactions. Future studies investigating tissue-specific elastic fiber assembly may lead to novel therapeutic interventions for ARCL1B and other disorders of elastic fiber assembly.

## INTRODUCTION

Extracellular matrix (ECM) proteins play an integral role in maintaining arterial wall integrity. Perturbations or deficiencies of several ECM proteins have been shown to alter the structure, biomechanical properties, and/or cell signaling within the arterial wall, leading to disease. For instance, mutations in fibrillin 1, transforming growth factor- $\beta$  (TGF $\beta$ ) receptor type 2, collagen 3A1, and lysyl oxidase (LOX) cause Marfan syndrome, Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, and familial thoracic aortic aneurysm, respectively, all of which have weakening of large arterial wall and development of ascending aortic aneurysm as features. Recently, mutations in fibulin-4 (*FBLN4*), also known as epidermal growth factor (EGF)-containing fibulin-like extracellular matrix protein 2 (*EFEMP2*), were described in humans with autosomal recessive cutis laxa type 1B (ARCL1B) (1–9). In addition to inelastic or redundant skin, some of the hallmark features of this disease include arterial tortuosity, aortic aneurysm, and pulmonary emphysema. Other more variable presentations include abnormalities of the skeletal system (10, 11).

FBLN4 belongs to a seven-member family of ECM proteins that share significant sequence and structural homology characterized by a C-terminal fibulin domain preceded by repeated Ca<sup>2+</sup>-binding EGF (cbEGF)-like motifs (12–14). Originally discovered through sequence homology to fibulin-1, fibulin-2, and fibulin-3 (15), FBLN4 is known to play a critical role in elastic fiber formation. *Fbln4* knockout (KO) mice die perinatally from severe lung and vascular abnormalities, including failure of alveolar septation, arterial tortuosity, aneurysms,

and rupture due to the absence of intact elastic fibers (16). In contrast, smooth muscle-specific KO and hypomorphic mouse models (17–19) of *Fbln4* show elastic fiber fragmentation, arterial tortuosity, and aneurysmal dilation of the ascending aorta (20, 21), suggesting that elastic fiber assembly is negatively affected when FBLN4 levels fall below a critical level.

How FBLN4 functions in elastic fiber assembly is not known. In vitro data show that the N terminus of FBLN4 can bind the propeptide of LOX and promote the association of LOX with tropoelastin (18, 22). This, in addition to the fact that the *Lox* null mouse model has features in common with the *Fbln4* KO mouse model (23, 24), has led to the currently accepted hypothesis that FBLN4 functions to deliver LOX to tropoelastin to facilitate cross-linking.

To study the effects of *FBLN4* missense mutations in vivo, Igoucheva *et al.* (25) recently generated a knock-in mouse carrying the E57K mutation identified in humans. This was the first mutation identified in a human with ARCL1B (4). Skin biopsy from this patient showed fewer elastic fibers, and studies using dermal fibroblasts suggested that the mutant protein is poorly secreted, is unstable, or is unable to bind matrix, leading to aberrant elastic fiber formation and the resultant clinical phenotype (4). Initial characterization of *Fbln4*<sup>E57K/E57K</sup> mice showed that the mouse model recapitulates the clinical manifestations seen in humans, including loose skin, bent forelimbs, pulmonary emphysema, arterial tortuosity, and ascending aortic aneurysms (25). In addition to elastic fiber abnormalities in the skin and large arteries, collagen fibrils were irregularly shaped, with many large fibrils noted in the dermis of *Fbln4*<sup>E57K/E57K</sup> mice (25).

Here, we examined the functional consequences of the E57K mutation in *Fbln4* on the cardiovascular system and noted significant hypertension and large artery stiffness in mutant mice. Because blood pressure is primarily regulated by resistance/muscular arteries, we investigated the effect of the E57K mutation in *Fbln4* on the structure of

<sup>1</sup>Division of Nephrology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA. <sup>2</sup>Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110, USA. <sup>3</sup>Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.

\*Corresponding author. Email: chalabi@wustl.edu


muscular arteries and noted surprising differences between conduit and resistance arteries. Whereas elastic lamellae within the wall of large vessels of the mutant mouse were severely fragmented and vascular smooth muscle cells (SMCs) were disorganized, resistance ar-

teries were seemingly unaffected by the mutation. Furthermore, unlike the skin (25), where elastin levels were decreased, we observed no change in elastin content, as measured by desmosine levels, in large conduit or small resistance arteries. Our data suggest tissue-specific roles for FBLN4 in maintaining arterial wall integrity and raise the interesting possibility that the requirements for elastic fiber assembly differ depending on vessel and tissue type.


## RESULTS

### Adult *Fbln4*<sup>E57K/E57K</sup> mice have ascending aortic aneurysms, arterial tortuosity, and elastic fiber fragmentation

Because arterial aneurysms and tortuosity are hallmark features of humans carrying recessive mutations in *FBLN4* (4, 5, 10, 11), we used a mouse model carrying a known human *FBLN4* mutation (*Fbln4*<sup>E57K/E57K</sup>) to evaluate how the mutant protein influences cardiovascular development and integrity. Mice recessive for the mutation were born at the expected Mendelian ratio (25), were similar in size to their wild-type



**Fig. 1. *Fbln4*<sup>E57K/E57K</sup> mice develop arterial elongation, vascular tortuosity, ascending aortic aneurysms, elastic fiber fragmentation, and SMC disarray.** (A) Gross morphology of the thoracic aorta and its branches in adult *Fbln4*<sup>E57K/E57K</sup> mice and control (*Fbln4*<sup>+/+</sup> and *Fbln4*<sup>+/-E57K</sup>) littermates injected with yellow latex to visualize the vasculature. Arrows indicate aortic root dilatation and ascending aortic aneurysm seen in approximately half of *Fbln4*<sup>E57K/E57K</sup> mice; arrowheads indicate the different angles at which arterial branches come off the aortic arch. Arterial tortuosity and elongation are noted in all *Fbln4*<sup>E57K/E57K</sup> mice. (B to D) VVG (Verhoeff-van Gieson) stain (B) and transmission electron micrographs of the ascending aorta of 3-month-old *Fbln4*<sup>E57K/E57K</sup> mice and littermate controls at two different magnifications (C versus D). In addition to severe elastic fiber fragmentation, there is increased medial wall thickness and SMC disarray in the aorta of *Fbln4*<sup>E57K/E57K</sup> mice. At higher magnification (D), the moth-eaten or spongy appearance of the fragmented elastic fibers is appreciated in the aorta of *Fbln4*<sup>E57K/E57K</sup> mice. In addition, there is loss of smooth muscle contact with elastic fibers in *Fbln4*<sup>E57K/E57K</sup> vessels. Scale bars, 8 μm (C) and 4 μm (D). Asterisks indicate vessel lumen.



**Fig. 2. Elastic fiber fragmentation and SMC disarray in descending aorta of *Fbln4*<sup>E57K/E57K</sup> mice.** Transmission electron micrographs of descending aorta of 3-month-old *Fbln4*<sup>E57K/E57K</sup> and littermate mice (*Fbln4*<sup>+/+</sup> and *Fbln4*<sup>+/-E57K</sup>). (A and B) In addition to severe elastic fiber fragmentation, there is increased medial wall thickness and SMC disarray in the aorta of *Fbln4*<sup>E57K/E57K</sup> mice. At higher magnification, the moth-eaten or spongy appearance of the fragmented elastic fibers (B) and variable (arrows = larger) collagen fibril size (C) are appreciated in the aorta of *Fbln4*<sup>E57K/E57K</sup> mice. Asterisks indicate vessel lumen.




(WT) littermates (fig. S1), and had no increased mortality by 1 year of age. As shown in Fig. 1A, arterial elongation and tortuosity, as well as variable branching angles of arteries from the aortic arch, were noted in all *Fbln4*<sup>E57K/E57K</sup> mice, but not in WT or heterozygous littermates. Ascending aortic aneurysms and/or aortic root dilations were noted in approximately half of the *Fbln4*<sup>E57K/E57K</sup> animals. No aneurysms or dilations were seen in any other arterial segment or in WT or heterozygous littermates.

VVG staining of the ascending aorta of *Fbln4*<sup>E57K/E57K</sup> mice showed extensive elastic fiber fragmentation and disarray (Fig. 1B) as well as increased wall thickness (fig. S2) due mainly to thickening of the medial layer. Ultrastructural examination of the large vessels by electron microscopy showed moth-eaten or spongy appearance of elastin and round-shaped SMCs reminiscent of dedifferentiated cells that are detached from the elastic lamellae (Fig. 1C). Notably, the severity of elastic fiber fragmentation and disarray was variable in different regions

of the same vessel cross section. The arterial wall abnormalities were seen in both aneurysmal and nonaneurysmal areas of the ascending aorta, and there was no evidence of arterial calcification, as shown by negative von Kossa staining (fig. S3), up to 1 year of age. Similar ultrastructural changes were evident in the wall of the descending thoracic aorta (Fig. 2, A and B), although this vascular segment did not develop aneurysms. In addition to the elastic fiber and SMC abnormalities, collagen fibril size was slightly variable, with significantly larger fibrils in the adventitia of *Fbln4*<sup>E57K/E57K</sup> aorta (Fig. 2C).

### *Fbln4*<sup>E57K/E57K</sup> mice have large artery stiffness and systolic hypertension

Perturbations in elastin/collagen content or elastic fiber integrity often lead to changes in arterial stiffness. When the mechanical properties of large arteries in adult *Fbln4*<sup>E57K/E57K</sup> mice were characterized, we found that the ascending aortae and carotid arteries reached maximal



**Fig. 3. *Fbln4*<sup>E57K/E57K</sup> mice develop large artery stiffness and systolic hypertension.** Pressure-diameter relationships of ascending aorta (A) and carotid arteries (B) from 3- to 6-month-old *Fbln4*<sup>E57K/E57K</sup> male mice and littermates (*Fbln4*<sup>+/+</sup> and *Fbln4*<sup>+/E57K</sup>). At each pressure, the vessel outer diameter was compared to that of WT vessels using two-way analysis of variance (ANOVA) with Tukey's multiple comparisons test. *n* = 7 to 10 for ascending aorta except for aneurysmal *Fbln4*<sup>E57K/E57K</sup>, where *n* = 3 (A) and 8 to 9 (B) for carotid arteries. Arterial systolic blood pressure (SBP) (C), diastolic blood pressure (DBP) (D), and pulse pressure (PP) (E) of 3- to 4-month-old *Fbln4*<sup>E57K/E57K</sup> male and female mice and littermates. PP was calculated as the difference between measured SBP and DBP. Pressure was compared among all genotypes using one-way ANOVA with Tukey's multiple comparisons test. *n* = 10 to 12 per genotype. (F) Heart weight-to-body weight ratios between the three genotypes presented in two distinct age groups. At 6 to 7 months of age, mice with aortic root dilatation developed cardiac hypertrophy. Data are means ± SD. \**P* < 0.05, \*\*\*\**P* < 0.0001.


dilation at lower pressures than those of heterozygous or WT mice, indicating that they have stiffer large arteries (Fig. 3, A and B). Because of significant differences in the outer diameter of aneurysmal versus nonaneurysmal *Fbln4*<sup>E57K/E57K</sup> ascending aortae, the data were separated into two groups. As shown in Fig. 3A, although the aneurysmal *Fbln4*<sup>E57K/E57K</sup> ascending aortae have a larger diameter at 0 mmHg, their pressure-diameter curve has the same compliance as that of nonaneurysmal *Fbln4*<sup>E57K/E57K</sup> aortae (that is, parallel curves), suggesting that the material properties or mechanics of *Fbln4*<sup>E57K/E57K</sup> ascending aortae are not influenced by the presence of an aneurysm.

To assess the physiologic consequences of elastic fiber fragmentation and large artery stiffness, we measured arterial blood pressure and found that *Fbln4*<sup>E57K/E57K</sup> mice have significant systolic hypertension with widened PP, but no elevation in DBP compared to WT or heterozygous littermates (Fig. 3, C to E). The systolic hypertension and widened PP were completely penetrant and independent of

aneurysm formation. There were no differences in circumferential arterial stiffness or blood pressure between WT and heterozygous (*Fbln4*<sup>+E57K</sup>) mice (Fig. 3, A to E). Heart rate was not different among all three genotypes (fig. S4). As shown in Fig. 3F, we noted differences in *Fbln4*<sup>E57K/E57K</sup> heart size at 6 months of age. Echocardiographic evaluation of *Fbln4*<sup>E57K/E57K</sup> mice with aortic root dilation at 6 weeks of age showed normal shortening fraction. However, by 6 months of age, the mice with the larger heart sizes had aortic root dilation and aortic root insufficiency, leading to worse shortening fraction, suggesting that cardiomyopathy develops over time (table S1).

**Small resistance arteries have normal elastic fibers and normal wall structure in *Fbln4*<sup>E57K/E57K</sup> mice**

Blood pressure is largely regulated by small resistance vessels. To determine whether these vessels were also affected by the E57K mutation, we examined the ultrastructure of saphenous arteries and second-order



**Fig. 4. The E57K mutation in *Fbln4* has differential effects on elastic versus resistance artery integrity.** Alexa Fluor 633 hydrazide staining of carotid (A, a and b) and renal arteries (B, a and b) from 3-month-old *Fbln4*<sup>E57K/E57K</sup> (b) and WT littermate mice (a). Red indicates elastic fibers, and blue depicts nuclear staining with 4',6-diamidino-2-phenylindole (DAPI). Mutant vessels are indistinguishable from WT vessels using Alexa Fluor 633 hydrazide staining. Transmission electron micrographs of carotid (A, c and d) and renal arteries (B, c and d) from 3-month-old *Fbln4*<sup>E57K/E57K</sup> mice are shown. Micrographs in (d) are higher magnification of the inset demarcated in (c). Note the moth-eaten appearance of the inner two elastic fibers compared to the normal appearance of the outer two elastic fibers in the carotid artery (A, d). (C) Transmission electron micrographs of second-order mesenteric arteries from 3-month-old (a and b) and 1-year-old (c and d) *Fbln4*<sup>E57K/E57K</sup> and WT littermate mice in addition to 1-year-old renal arteries. Asterisks indicate vessel lumen. (D) Table summarizing the presence or absence of elastic fiber abnormalities in the different *Fbln4*<sup>E57K/E57K</sup> arteries examined.

mesenteric arteries of 3-month-old *Fbln4*<sup>E57K/E57K</sup> mice and littermate controls. Surprisingly, these vessels showed none of the structural abnormalities evident in the large vessels and were similar to vessels from heterozygous mutant or WT mice (Fig. 4C, a and b, and fig. S5). The internal elastic lamina of *Fbln4*<sup>E57K/E57K</sup> mesenteric and saphenous arteries showed the normal amorphous appearance of elastin on electron microscopy, as opposed to the moth-eaten and fragmented appearance noted in large vessels. In addition, the medial layer of


*Fbln4*<sup>E57K/E57K</sup> mesenteric and saphenous arteries consisted of the typical two to three SMC layers and was not thickened compared to WT arteries.

### The elastic laminae of *Fbln4*<sup>E57K/E57K</sup> arteries are adversely affected in conducting but not muscular arteries


The normal elastic fibers present in mesenteric and saphenous arteries suggested that the E57K mutation has different effects on elastin assembly in muscular arteries as compared to elastic arteries. Visualization of elastic fibers with Alexa Fluor 633 hydrazide in the carotid (Fig. 4A, a and b) and renal (Fig. 4B, a and b) arteries did not indicate any significant structural differences between WT and *Fbln4*<sup>E57K/E57K</sup> vessels. However, ultrastructural examination of *Fbln4*<sup>E57K/E57K</sup> common carotid artery, which has four elastic lamellae, by transmission electron microscopy showed moth-eaten appearance of the two inner elastic lamellae, whereas the two outer laminae closest to the adventitia were unaffected (Fig. 4A, c and d). In contrast, ultrastructural examination of *Fbln4*<sup>E57K/E57K</sup> main renal artery, which only has an internal and an external elastic lamina (muscular artery), showed intact elastic laminae and normal arterial wall structure (Fig. 4B, c and d). To assess whether elastic fiber abnormalities developed over time with aging in *Fbln4*<sup>E57K/E57K</sup> muscular arteries, we examined the ultrastructure of mesenteric and renal arteries at 1 year of age. As shown in Fig. 4C, the elastic laminae of *Fbln4*<sup>E57K/E57K</sup> muscular arteries remained intact at 1 year of age. A table summarizing elastic fiber abnormalities noted by electron microscopy in the different *Fbln4*<sup>E57K/E57K</sup> arteries examined is available in Fig. 4D.

### Elastic fiber fragmentation and medial wall thickness of *Fbln4*<sup>E57K/E57K</sup> ascending aortae are present at birth

To determine whether elastic fiber fragmentation in the *Fbln4*<sup>E57K/E57K</sup> ascending aorta is a problem with fiber assembly in early development



**Fig. 5. Large artery elastic fiber fragmentation and medial wall thickening occur developmentally in *Fbln4*<sup>E57K/E57K</sup> mice.** Transmission electron micrographs of P1 ascending aorta from *Fbln4*<sup>+/+</sup> (A and B) and *Fbln4*<sup>E57K/E57K</sup> (C and D) mice. Asterisks indicate vessel lumen. Scale bars, 10 μm.



**Fig. 6. E57K mutation in *Fbln4* does not alter arterial elastin or collagen content.** Desmosine (A and C) and hydroxyproline (B and D) content were determined in ascending aortae (A and B) and mesenteric arteries (C and D) of 3- to 4-month-old *Fbln4*<sup>E57K/E57K</sup> (closed triangles) male and female mice and littermates (open circles, *Fbln4*<sup>+/+</sup>; gray squares, *Fbln4*<sup>+/E57K</sup>).



or is a postnatal degenerative process that occurs with aging, we examined the ultrastructure of ascending aorta right after birth [postnatal day 1 (P1)]. As shown in Fig. 5, there is significant elastic fiber fragmentation and medial wall thickening in *Fbln4*<sup>E57K/E57K</sup> ascending aorta compared to WT vessels, suggesting that mutant FBLN4 leads to abnormal elastic fiber formation during fetal development. In addition, SMCs in the mutant aorta were less organized and did not show the tightly layered structure seen with WT animals.

### The E57K mutation in *Fbln4* does not affect arterial collagen or elastin content or elastic fiber gene expression


To determine the effect of E57K mutation in *Fbln4* on elastin cross-linking and collagen concentration in arteries, we measured desmosine and hydroxyproline content in ascending aorta (Fig. 6, A and B) and carotid (fig. S6) and mesenteric arteries (Fig. 6, C and D) of 3- to 4-month-old *Fbln4*<sup>E57K/E57K</sup> and littermate mice. Desmosine and hydroxyproline content was equivalent in vessels from all three genotypes, indicating normal elastin and collagen cross-linking and protein levels. There were also no significant differences in the expression of the elastic fiber genes *Fbln4*, *Fbln5*, elastin (*Eln*), *Lox*, or fibrillin 1 (*Fbn1*) in the ascending aorta or mesenteric arteries of all three genotypes (Fig. 7, A and B). Similar results were seen in the lung (fig. S7). Because elastic fiber formation starts in late gestation and continues until maturation at ~P21, we sought to determine the effect of the E57K mutation in *Fbln4* on elastic fiber gene expression while elastin assembly is ongoing. As shown in Fig. 7 (C and D) and similar to what was seen in adult vessels, the E57K mutation in *Fbln4* did not affect elastic fiber gene expression in P7 aorta or mesenteric arteries.

### FBLN4(E57K) protein level is reduced in extracts of *Fbln4*<sup>E57K/E57K</sup> ascending aorta, but not mesenteric arteries

Western blot analysis of urea extracts from the adult ascending aorta of *Fbln4*<sup>E57K/E57K</sup> and littermate control mice showed significantly reduced protein in the aorta of mutant mice, an observation confirmed by immunofluorescence staining of FBLN4 protein in ascending aorta and carotid artery (Fig. 8, A and C). However, in mesenteric arteries, the amount of FBLN4(E57K) protein was equivalent to WT (Fig. 8B). Similar trends of FBLN4 protein levels were observed in aorta and mesenteric arteries of P7 *Fbln4*<sup>E57K/E57K</sup> and littermate mice (fig. S8). The effect of the E57K mutation on FBLN4 secretion was also tested in dermal fibroblasts. As shown in fig. S9 and consistent with previous results (25), there was significantly more protein in the cell lysates of *Fbln4*<sup>E57K/E57K</sup> cells and less in the culture medium compared to cells from WT or heterozygous mice, suggesting reduced mutant protein secretion.


### DISCUSSION

Homozygous or compound heterozygous mutations in *FBLN4* (*EFEMP2*) lead to ARCL1B, a devastating multisystem disorder characterized by loose inelastic skin, arterial tortuosity and aneurysms, pulmonary emphysema, and skeletal abnormalities (1–11). Recently, a mouse model carrying a missense mutation in *Fbln4* (E57K) found in two independent infants with ARCL1B was generated (25). Focusing primarily on the cutaneous and skeletal features, initial characterization of *Fbln4*<sup>E57K/E57K</sup> mice identified abnormalities in elastic fibers and collagen fibrils as the basis for the observed phenotypes (25). By characterizing the cardiovascular phenotype of this



**Fig. 7. E57K mutation in *Fbln4* does not affect arterial elastic fiber gene expression.** Expression of indicated elastic fiber-associated genes (*Fbln2*, fibulin-2; *Fbln4*, fibulin-4; *Fbln5*, fibulin-5; *Eln*, elastin; *Lox*, lysyl oxidase; *Fbn1*, fibrillin 1) in ascending aortae (A and C) and mesenteric arteries (B and D) of 3- to 4-month-old (A and B) and P7 (C and D) *Fbln4*<sup>E57K/E57K</sup> (closed bars) and littermate mice (open bars, *Fbln4*<sup>+/+</sup>; gray bars, *Fbln4*<sup>+/-E57K</sup>). Gene expression was normalized to that of *Gapdh*. Data are means  $\pm$  SD and were compared using one-way ANOVA with Tukey's multiple comparisons test.  $n = 3$  to 8 per genotype.





**Fig. 8. FBLN4(E57K) protein level is reduced in ascending aortae, but not in mesenteric arteries of adult mice.** Western blot analysis of urea extracts from ascending aortae (A) and mesenteric arteries (B) of *Fbln4*<sup>E57K/E57K</sup> mice and littermate controls using a polyclonal rabbit anti-FBLN4 antibody. FBLN4 level was normalized to that of β-actin. The normalized data are represented in the bar graphs on the right. *n* = 4 to 7 per genotype. Data are means ± SD and were compared using one-way ANOVA with Tukey's multiple comparisons test. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001. (C) Immunofluorescence of ascending aorta and carotid artery sections of 3-month-old *Fbln4*<sup>E57K/E57K</sup> and WT control mice. Green, FBLN4; red, autofluorescence of elastic fibers; blue, DAPI. Asterisks indicate vessel lumen.

mouse, we identified several novel findings that extend our knowledge and raise further questions on the role of FBLN4 in elastic fiber formation and in maintaining arterial wall integrity, not only between different tissues, such as the skin and the vasculature, but also along the arterial tree.

All *Fbln4*<sup>E57K/E57K</sup> mice had systolic hypertension with widened PP and large artery stiffness. Higher systolic pressure contrasts with the *Fbln4*<sup>SMKO</sup> and the hypomorphic *Fbln4* mouse models that exhibited normal SBP but lower DBP (20, 21). This difference, coupled with the fact that *Fbln4*<sup>E57K/E57K</sup> mice live to over 1 year of age, suggests that the E57K mutation is not a loss-of-function mutation but may alter or interfere with normal FBLN4 function or availability. Cardiac dysfunction and hypertrophy were only seen in *Fbln4*<sup>E57K/E57K</sup> mice with aortic insufficiency secondary to aortic root dilation at 6 months of age, but not at 6 weeks of age, indicating that cardiac dysfunction is exacerbated by the aortic insufficiency, arterial stiffness, and systolic hypertension seen with mutant FBLN4.

*Fbln4*<sup>E57K/E57K</sup> mice developed arterial tortuosity and elongation, as well as ascending aortic aneurysms that were confined to the as-

cending aorta. No dilation or narrowing was noted anywhere else along the arterial tree. The ascending aorta is the initial vessel segment that senses the volume/pressure ejected with each ventricular contraction; therefore, with an abnormal wall, it may be at greatest risk for dilation. Alternatively, the restriction of aneurysm formation to the ascending aorta may be a consequence of the differing developmental origins of SMCs in the ascending aorta (neural crest), as opposed to SMCs derived from the somatic or paraxial mesoderm that make up the rest of the arterial tree (26). Although the variable severity of elastic fiber fragmentation may explain why only 50% of the homozygous mutant mice developed ascending aortic aneurysms (25), one cannot rule out the presence of potential modifiers. It is important to note that the presence of fragmented elastic fibers and elevated blood pressure alone do not explain aneurysm formation. Humans or mice with elastin insufficiency (*ELN*<sup>−/−</sup>), or mice completely lacking elastin (*Eln*<sup>−/−</sup>), are hypertensive and develop vascular stenosis but their ascending aortae do not dilate (27–29). Similarly, mice lacking fibulin-5 or humans with *FBLN5* mutations (autosomal recessive cutis laxa type 1A) have fragmented elastic fibers, arterial tortuosity and elongation, and elevated SBP but do not develop aneurysms (30, 31). Therefore, changes in cell-cell or cell-ECM signaling may be responsible for aneurysm development. Increased TGFβ signaling has been implicated in aneurysm formation in the hypomorphic and SMKO *Fbln4* mouse models, as well as mouse models of Marfan and Loeys Dietz syndromes (17, 20, 32–34). Future studies will determine whether altered TGFβ signaling plays a role in aneurysm formation in *Fbln4*<sup>E57K/E57K</sup> mice.

An interesting finding in this study was the unchanged elastin content, as assessed by desmosine levels, in both the ascending aorta and carotid arteries of *Fbln4*<sup>E57K/E57K</sup> mice despite extensive elastic fiber fragmentation. Even with normal elastin levels, the mutant vessels are significantly stiffer than WT, which indicates that the integrity and organization of elastin, and not quantity alone, are important for normal vessel function. A significant increase in desmosine content was recently reported in the ascending aorta of SMC-specific *Fbln4* KO (SMKO) mice (35). Normal or increased elastin cross-linking in the mutant aortae is in sharp contrast to the *Fbln4*<sup>E57K/E57K</sup> skin, where desmosine was decreased (25), and to the global *Fbln4* KO mouse model, where elastin cross-links were decreased by 94% in the aorta (16). These tissue-specific differences are intriguing. Although not well elucidated, evidence for tissue-specific differences in elastic fiber assembly were found in a mouse model of autosomal dominant cutis laxa (ADCL). In this mouse model, a bacterial artificial chromosome carrying the human elastin gene with a single base pair deletion known to result in ADCL was expressed as a transgene in mice. In mice carrying the transgene, skin and lung incorporated mutant elastin, whereas the aorta incorporated very low levels of the mutant protein, suggesting that elastin assembly was different in the aorta than in the skin and lung (36).

Another striking example of tissue-specific differences in FBLN4 function is the normal appearance of elastin in the *Fbln4*<sup>E57K/E57K</sup> muscular arteries, specifically mesenteric, saphenous, and renal arteries. To our knowledge, all current data in the literature presume that the process of elastic fiber formation, particularly arterial elastic lamellae, is similar along the arterial tree. The data presented herein suggest that elastic lamellae may develop differently in different arterial beds. The finding that the muscular vessels are unaffected by the *Fbln4* mutation suggests either that FBLN4 is not necessary for resistance or muscular artery elastic fiber formation or that there is functional compensation by another protein.

FBLN4's presumed function in elastic fiber assembly is to initiate cross-linking by guiding LOX to tropoelastin (18). The fact that desmosine levels are essentially normal suggests that the cross-linking function of LOX is intact in *Fbln4*<sup>E57K/E57K</sup> mice. This suggests either that the E57K mutation affects secretion or amount of the protein rather than its function or that FBLN4 is not necessary for cross-linking but rather serves another function important for elastic fiber formation and integrity that is altered by the E57K mutation. This latter possibility is supported by the normal cross-linking seen when FBLN4 is deleted from arterial SMCs (35). Fibulins have been shown to play a role in maintaining cell morphology, growth, and adhesion (14, 37–41). To that end, SMC contractile genes were down-regulated in the ascending aorta of *Fbln4*<sup>SMKO</sup> mice, suggesting that FBLN4 may play a role in SMC differentiation and maturation (19). It is clear that FBLN4 is crucial developmentally because *Fbln4*<sup>E57K/E57K</sup> mice had elastic fiber fragmentation and increased large vessel medial wall thickness as early as P1, but its exact role in vessel wall development or homeostasis remains unclear.

In conclusion, we have characterized the structural and functional consequences of an *FBLN4* mutation associated with ARCL1B on the cardiovascular system. In addition to ascending aortic aneurysms, arterial tortuosity, and elongation, homozygous mutant mice have stiff large arteries and systolic hypertension, a finding not described or reported in ARCL1B patients (1–11). Although previously known to be associated with elastic fiber formation in large arteries, data presented herein indicate that FBLN4 is not required for elastic fiber formation in small muscular arteries, thereby calling into question the assumed requirement of FBLN4 in elastic fiber assembly. This model will provide a useful tool to study tissue-specific differences in elastic fiber formation and to better understand the role of FBLN4 in elastic fiber assembly.

## MATERIALS AND METHODS

### Mice

Generation of mice carrying a knock-in mutation (G to A) in exon 4, leading to substitution of glutamate to lysine at amino acid 57, was previously described (25). Briefly, C57BL/6 embryonic stem cells were targeted with a vector carrying the point mutation in *Fbln4* and loxP/FRT-flanked Neo cassette in intron 4. After identification of germline transmission of the targeted allele, the neomycin resistance gene was removed by crossing the resulting mice with mice ubiquitously expressing FLP1 recombinase on the C57BL/6 background. Mice heterozygous for knock-in allele were intercrossed to generate mice of all three genotypes (*Fbln4*<sup>+/+</sup>, *Fbln4*<sup>+/E57K</sup>, and *Fbln4*<sup>E57K/E57K</sup>) used in the experiments, as described in this article. Tail DNA was used to genotype the mice, as previously described (25). The mice were housed under standard conditions with free access to food and water. All protocols were approved by the Animal Studies Committee of Washington University School of Medicine.

### Gross morphology

After euthanasia with CO<sub>2</sub>, the abdominal and chest walls of *Fbln4*<sup>+/+</sup>, *Fbln4*<sup>+/E57K</sup>, and *Fbln4*<sup>E57K/E57K</sup> adult mice were dissected away. To drain the blood from the vasculature, 5 ml of 1× phosphate-buffered saline (PBS) (pH 7.4) was flushed through the apex of left ventricle after transecting the left common iliac (32). Yellow latex (1 to 2 ml) (Ward's Science) was then injected through the left ventricle. The yellow latex was allowed to set by keeping the mice moist for 3 to 4 hours

at 4°C. Mice were then fixed in 10% neutral buffered formalin (Fisher Scientific) at 4°C overnight, after which they were stored in 70% ethanol at 4°C until dissection was performed.

### Vessel dissection for histology or electron microscopy

After euthanasia with CO<sub>2</sub>, the abdominal and chest walls of *Fbln4*<sup>+/+</sup>, *Fbln4*<sup>+/E57K</sup>, and *Fbln4*<sup>E57K/E57K</sup> mice were dissected away, and an incision was made through the right atrium. Five milliliters of 1× PBS (pH 7.4) was flushed through the apex of the left ventricle. Maintaining the needle in the same position, we exchanged the PBS for 10% neutral buffered formalin (Fisher Scientific), which was allowed to flow through the left ventricle at 95-cm H<sub>2</sub>O, equivalent to the mean arterial pressure. After pressure fixation, vessels (ascending aorta, descending aorta, carotid arteries, and/or mesenteric arteries) were dissected and placed at 4°C either in 10% neutral buffered formalin for histology or in a solution containing 2.5% glutaraldehyde and 0.1 M sodium cacodylate for electron microscopy.

### VVG and von Kossa staining

After fixation with neutral buffered formalin, vessels were washed with 1× PBS (twice for 15 min) and then dehydrated by running through an ethanol gradient (30, 50, and then 70% for 30 min each), after which they were taken to the Histology Core Facility, where dehydration was completed and the samples were paraffin-embedded and sectioned. Sections were deparaffinized with xylene and hydrated by running through an ethanol gradient (100, 90, 80, 70, 50, and then 30%), followed by distilled water. Von Kossa staining was performed by the Histology Core Facility, whereas VVG staining was performed following the IHC World protocol. Briefly, sections were stained in Verhoeff's solution for 30 min, differentiated in 2% ferric chloride for 1 to 2 min, treated with 5% sodium thiosulfate, and then counterstained with van Gieson's solution for 5 min. Solutions were purchased from American MasterTech. The sections were then dehydrated to 100% ethanol and treated with xylene before mounting with VectaMount (Vector Laboratories Inc.) and coverslip placement. Images were obtained using a Zeiss Axioskop 50 microscope and QCapture Pro software (Media Cybernetics Inc.).

### Transmission electron microscopy

After isolation, vessels were fixed in 2.5% glutaraldehyde and 0.1 M sodium cacodylate at 4°C overnight. Vessels were then sent to Washington University's Center for Cellular Imaging for processing and thin sectioning. Images were taken using a JEOL JEM-1400Plus transmission electron microscope that is equipped with an Advanced Microscopy Techniques XR111 high-speed, 4000 × 2000-pixel, phosphor-scintillated, 12-bit charge-coupled device (CCD) camera.

### Alexa Fluor 633 hydrazide staining

Vessels (left common carotid artery and right renal artery) from *Fbln4*<sup>+/+</sup>, *Fbln4*<sup>+/E57K</sup>, and *Fbln4*<sup>E57K/E57K</sup> mice were dissected and frozen in optimal cutting temperature (OCT) compound (Sakura Finetek) at –80°C. With a cryostat, 3-μm sections were obtained and fixed in 4% paraformaldehyde for 10 min at 4°C. Sections were washed twice with 1× PBS for 5 min each and then incubated in 1:1000 of a 2 mM Alexa Fluor 633 hydrazide (Life Technologies) stock in 1% bovine serum albumin (BSA)/1% fish gelatin/0.05% Triton-X in 1× PBS for 5 min at room temperature. Sections were then washed twice with 1× PBS for 5 min each. Slides were mounted with DAPI Fluoromount-G (SouthernBiotech) and coverslipped. Images were obtained using a Zeiss Axioskop 50 microscope and QCapture Pro software (Media Cybernetics Inc.).

## Blood pressure measurement

Mice were anesthetized with 1.5% isoflurane and maintained on a heating pad to keep their body temperature at 37°C, monitored via a rectal thermometer. A 2- to 3-mm midline incision was made in the neck; the lobes of the thymus were separated to expose the right common carotid artery. After clamping and making a small nick in the right common carotid artery, a Millar pressure transducer (model SPR-671) was introduced and advanced to the ascending aorta. SBP, DBP, and heart rate were recorded using the PowerLab data acquisition system (ADInstruments), and data were analyzed using LabChart 7 for Mac software (ADInstruments).

## Compliance studies

Arterial pressure-diameter curve measurements were performed as previously described (42). Briefly, after blood pressure measurement, mice were euthanized under isoflurane anesthesia, and the ascending aorta and the left common carotid artery were excised and placed in physiology saline solution (PSS) composed of 130 mM NaCl, 4.7 mM KCl, 1.6 mM CaCl<sub>2</sub>, 1.18 mM MgSO<sub>4</sub>·7H<sub>2</sub>O, 1.17 mM KH<sub>2</sub>PO<sub>4</sub>, 14.8 mM NaHCO<sub>3</sub>, 5.5 mM dextrose, and 0.026 mM EDTA (pH 7.4). After the vessels were cleaned of surrounding fat, they were mounted on a pressure arteriograph (Danish Myo Technology) and maintained in PSS at 37°C. Vessels were visualized with an inverted microscope connected to a CCD camera and a computerized system, which allows continuous recording of vessel diameter. Because intravascular pressure was increased from 0 to 175 mmHg by 25-mmHg increments, the vessel outer diameter was recorded at each step (12 s per step). The average of three measurements at each pressure was reported.

## Echocardiography

Noninvasive cardiac ultrasound examination of 6-week-old and 6-month-old *Fbln4*<sup>+/+</sup> and *Fbln4*<sup>E57K/E57K</sup> was performed under light anesthesia by the Mouse Cardiovascular Phenotyping Core at Washington University School of Medicine in St. Louis. A VisualSonics echocardiography machine (FUJIFILM VisualSonics Inc.) with a 15-MHz linear transducer was used to characterize the structure and function of the heart and great vessels.

## Desmosine and hydroxyproline assays

After completion of compliance studies, ascending aorta and carotid arteries were dried of excess physiologic saline solution and kept at –20°C until protein quantification, and desmosine/hydroxyproline measurement assays were performed as previously described (42). All mesenteric artery branches from each mouse were dissected and included as one sample. Briefly, each sample was hydrolyzed with 20 µl of 6 N hydrochloric acid (Thermo Scientific) at 105°C for 48 hours. Samples were dried at 65°C for 90 min in SpeedVac, and each pellet was dissolved in 400 µl of water and filtered with a 0.45-µm filter.

A ninhydrin-based assay was used to determine the protein content of each sample (43). An aliquot of each hydrolyzed sample was reacted with 100 µl of 100 mM ninhydrin [dissolved in 75% ethylene glycol containing SnCl<sub>2</sub> (2.5 mg/ml) and 1 M sodium acetate (pH 5.5)] at 85°C for 10 min. The protein content of each sample was determined by measuring the absorbance at 575 nm and comparing it to a calibration standard for protein hydrolysis (Pickering Laboratories).

A chloramine-T colorimetric assay was used to determine hydroxyproline content (44). An aliquot of each hydrolyzed sample was oxidized with 1.5 mg of chloramine-T for 20 min at room temperature and then reacted with 20 mg of *p*-dimethylaminobenzaldehyde

dissolved in propanol containing 20% perchloric acid for 20 min at 65°C. Samples were done in duplicate. Absorbance at 550 nm was measured using a Synergy H4 Multi-Mode plate reader, and hydroxyproline content was determined by comparison to a standard curve. Reagents for this assay were purchased from Sigma-Aldrich.

To determine desmosine content in the hydrolyzed samples, a competitive enzyme-linked immunosorbent assay was used (45). Briefly, an aliquot of hydrolysate was added to a well of a desmosine-ovalbumin-coated 96-well plate (Elastin Products Company). Rabbit anti-desmosine antibody (1:4000) (Elastin Products Company) was added to each well and incubated at room temperature for 1 hour. After unbound antibodies were washed off, a goat anti-rabbit secondary antibody conjugated to horseradish peroxidase (HRP) (NA934V, GE Health Sciences) was added. After 1 hour of incubation, SureBlue TMB peroxidase substrate was added to determine peroxidase activity by measuring the absorbance at 650 nm. Desmosine content was determined by extrapolation from a desmosine standard curve (Elastin Products Company) run on the same plate.

## RNA isolation and quantitative real-time reverse transcription polymerase chain reaction

After euthanasia with CO<sub>2</sub>, the chest cavity was exposed, and 5 ml of 1× PBS was flushed through the apex of the left ventricle after snipping the right atrium. Ascending aorta (from the root up to, but before, the first branch of the aortic arch) for adult mice and all thoracic aorta for P7 mice, left lung, and mesenteric arteries (all branches for each mouse) were isolated and stored in RNAlater at –80°C until mRNA was isolated using TRIzol following the manufacturer's protocol (Life Technologies). Total RNA (1 µg) was reverse-transcribed using High-Capacity RNA-to-cDNA Kit per the manufacturer's protocol (Life Technologies). Real-time polymerase chain reaction (PCR) was done using 1 µl of complementary DNA template, TaqMan Fast Universal PCR Master Mix, and TaqMan assays (primers/probes) obtained from Life Technologies. Reactions were run in duplicate on the ViiA real-time PCR system, and experimental gene expression was normalized to that of *Gapdh*. TaqMan assays used in this study are Mm00514670\_m1 (*Eln*), Mm00445429\_m1 (*Efemp2*), Mm00488601\_m1 (*Fbln5*), Mm00495386\_m1 (*Lox*), Mm00514908\_m1 (*Fbn1*), Mm99999915\_g1 (*Gapdh*), Mm02342430\_g1 (*Ppia* or *cyclophilin*), and Mm00484266\_m1 (*Fbln2*).

## Mouse tissue protein extraction

Ascending aorta and most branches of mesenteric arteries were dissected after flushing the vasculature with 1× PBS through the apex of the left ventricle. Tissues were stored at –80°C until protein extraction was performed. Tissues were homogenized using TissueLyser II (Qiagen) at 30 Hz for 5 min in an 8 M urea solution in 16 mM Na<sub>2</sub>HPO<sub>4</sub> (pH 7) containing protease inhibitors, and homogenates were incubated at 4°C overnight. After centrifugation, the supernatant was diluted to 2 M urea using 16 mM Na<sub>2</sub>HPO<sub>4</sub>, and bicinchoninic acid (BCA) assay (Bio-Rad) was performed to measure protein concentration. Protein was then precipitated using 10% trichloroacetic acid at 4°C for 1 hour. After centrifugation, the pellet was washed three times with ice-cold acetone and resuspended in Laemmli buffer containing dithiothreitol (DTT). The suspension was boiled for 5 min and used for SDS-polyacrylamide gel electrophoresis (SDS-PAGE).

## Primary mouse dermal fibroblast preparation and protein isolation

A 1 cm × 1 cm piece of skin from the back of P1 mice was cut into 1 mm × 1 mm fragments and incubated in 1× Dulbecco's modified



Eagle's medium containing 15% fetal bovine serum, 1% nonessential amino acids, 1% glutamate, and 1× penicillin-streptomycin solution in a 10-cm tissue culture dish.

Once confluent in a 10-cm dish (passage #2 or #3), cells were placed in serum-free culture media for 24 hours. Supernatant was removed and concentrated using Ultracel-30K centrifugal filters (EMD Millipore). Radioimmunoprecipitation assay buffer (1 ml) (Cell Signaling Technology) containing protease inhibitors was added to the cells and incubated at 4°C for 10 min. Cells were then scraped off and incubated at 4°C overnight. After centrifugation, the protein concentration of the supernatant was determined using the Bio-Rad BCA assay. DTT-containing Laemmli buffer was added to 11 µg of protein, and the sample was boiled for 5 min and used for SDS-PAGE.

### FBLN4 antibody generation and Western blotting

Protein sequences for all mouse fibulin family members (fibulin-1 to fibulin-7) were aligned using the online software Clustal Omega. A unique sequence in the N terminus of FBLN4 was identified as potentially antigenic (TDGYEWDADSQHC). Peptide synthesis and key-hole limpet hemocyanin conjugation, rabbit immunization, bleeding, and antigen affinity purification of the antibody were performed by GenScript. The resulting polyclonal rabbit anti-mouse FBLN4 antibody was used as the primary antibody for Western blotting. Protein from tissues (ascending aorta or mesenteric arteries), cell lysates (primary mouse dermal fibroblasts), or supernatants was subjected to SDS-PAGE on a 10% gel. Protein was transferred to a polyvinylidene difluoride membrane, which was then blocked in 5% milk/0.1% Tween 20 in 1× PBS at room temperature (RT) for 1 hour. Rabbit anti-mouse FBLN4 antibody in blocking solution (1:800) was then added and incubated overnight at 4°C. The membrane was washed three times with 0.1% Tween 20/1× PBS and incubated with a secondary antibody [1:4000 donkey anti-rabbit immunoglobulin G (IgG)-HRP, GE Healthcare] in blocking solution for 1 hour at RT. Immobilon Western HRP Substrate (EMD Millipore) was used for protein detection via the ChemiDoc MP imaging system (Bio-Rad). After blocking for 1 hour at RT, the membrane was then incubated in 1:4000 mouse anti-β-actin antibody (Sigma-Aldrich), followed by 1:10,000 goat anti-mouse IgG-HRP (KPL) to assess protein loading.

### Immunofluorescence

After euthanasia with CO<sub>2</sub>, the chest cavity was exposed, the right atrium was clipped, and 5 ml of 1× PBS was flushed through the apex of the left ventricle. Ascending aorta and carotid arteries were dissected and frozen in OCT medium (Tissue-Tek, Sakura Finetek) at −80°C. With a cryostat, 3-µm sections were placed on slides, fixed in ice-cold acetone for 10 min, and washed with 1× PBS. To minimize autofluorescence of elastic fibers in the green channel, sections were then treated with Chicago Sky Blue (Sigma, 0.5% solution in 1× PBS) for 5 min at RT. Sections were washed with 1× PBS, blocked in a solution containing 1% BSA + 1% fish gelatin + 0.05% Triton X-100 for 1 hour at RT, and incubated in 1:500 rabbit anti-mouse FBLN4 antibody in blocking solution overnight at 4°C. The sections were then washed with 1× PBS and incubated in 1:2000 goat anti-rabbit-Alexa Fluor 488 antibody (Life Technologies) and 1:10,000 DAPI in blocking solution at RT for 1 hour. Slides were washed with 1× PBS, mounted with ProLong Gold Antifade Mountant (Thermo Fisher Scientific), and coverslipped. Images were obtained using a Zeiss Axioskop 50 microscope and QCapture Pro software (Media Cybernetics Inc.).

### Statistical analysis

One-way or two-way ANOVA with Tukey's multiple comparisons test was used to determine differences between genotypes, as indicated in each figure legend. Statistical analyses were run using Prism 6 for Mac OS X (GraphPad Software Inc.). Data are presented as means ± SD. Differences were considered statistically significant when *P* was equal to or less than 0.05.

### SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at <http://advances.sciencemag.org/cgi/content/full/3/5/e1602532/DC1>

table S1. Echocardiographic data of *Fbln4*<sup>E57K/E57K</sup> and littermate WT mice.

fig. S1. *Fbln4*<sup>E57K/E57K</sup> mice are similar in size to their littermates.

fig. S2. *Fbln4*<sup>E57K/E57K</sup> ascending aortae have increased medial wall thickness.

fig. S3. *Fbln4*<sup>E57K/E57K</sup> ascending aortae do not develop calcification.

fig. S4. *Fbln4*<sup>E57K/E57K</sup> mice have similar heart rates to their heterozygous and WT littermates.

fig. S5. Internal elastic lamina is unaffected in *Fbln4*<sup>E57K/E57K</sup> saphenous arteries.

fig. S6. Homozygous E57K mutation in *Fbln4* does not alter arterial elastin or collagen content.

fig. S7. Homozygous E57K mutation in *Fbln4* does not alter ECM gene expression in lungs.

fig. S8. FBLN4(E57K) protein level is reduced in P7 ascending aorta, but not in mesenteric arteries.

fig. S9. FBLN4(E57K) protein secretion is impaired compared to WT FBLN4.

### REFERENCES AND NOTES

1. M. Dasouki, D. Markova, R. Garola, T. Sasaki, N. L. Charbonneau, L. Y. Sakai, M.-L. Chu, Compound heterozygous mutations in fibulin-4 causing neonatal lethal pulmonary artery occlusion, aortic aneurysm, arachnodactyly, and mild cutis laxa. *Am. J. Med. Genet. A* **143A**, 2635–2641 (2007).
2. C. Hebson, K. Coleman, M. Clabby, D. Sallee, S. Shankar, B. Loeys, L. Van Laer, B. Kogon, Severe aortopathy due to fibulin-4 deficiency: Molecular insights, surgical strategy, and a review of the literature. *Eur. J. Pediatr.* **173**, 671–675 (2014).
3. J. Hoyer, C. Kraus, G. Hammersen, J.-P. Geppert, A. Rauch, Lethal cutis laxa with contractural arachnodactyly, overgrowth and soft tissue bleeding due to a novel homozygous *fibulin-4* gene mutation. *Clin. Genet.* **76**, 276–281 (2009).
4. V. Huchtagowder, N. Sausgruber, K. H. Kim, B. Angle, L. Y. Marmorstein, Z. Urban, *Fibulin-4*: A novel gene for an autosomal recessive cutis laxa syndrome. *Am. J. Hum. Genet.* **78**, 1075–1080 (2006).
5. M. Iascone, M. E. Sana, L. Pezzoli, P. Bianchi, D. Marchetti, G. Fasolini, Y. Sadou, A. Locatelli, F. Fabiani, G. Mangili, P. Ferrazzi, Extensive arterial tortuosity and severe aortic dilation in a newborn with an *EFEMP2* mutation. *Circulation* **126**, 2764–2768 (2012).
6. M. Kappanayil, S. Nampoothiri, R. Kannan, M. Renard, P. Coucke, F. Malfait, S. Menon, H. K. Ravindran, R. Kurup, M. Faiyaz-Ul-Haque, K. Kumar, A. De Paepe, Characterization of a distinct lethal arteriopathy syndrome in twenty-two infants associated with an identical, novel mutation in FBLN4 gene, confirms fibulin-4 as a critical determinant of human vascular elastogenesis. *Orphanet J. Rare Dis.* **7**, 61 (2012).
7. R. Rajeshkannan, C. Kulkarni, M. Kappanayil, S. Nampoothiri, F. Malfait, A. De Paepe, S. Moorthy, Imaging findings in a distinct lethal inherited arteriopathy syndrome associated with a novel mutation in the FBLN4 gene. *Eur. Radiol.* **24**, 1742–1748 (2014).
8. M. Renard, T. Holm, R. Veith, B. L. Callewaert, L. C. Adès, O. Baspinar, A. Pickart, M. Dasouki, J. Hoyer, A. Rauch, P. Trapane, M. G. Earing, P. J. Coucke, L. Y. Sakai, H. C. Dietz, A. M. De Paepe, B. L. Loeys, Altered TGFβ signaling and cardiovascular manifestations in patients with autosomal recessive cutis laxa type I caused by fibulin-4 deficiency. *Eur. J. Hum. Genet.* **18**, 895–901 (2010).
9. S. L. Sawyer, F. Dicke, A. Kirtan, T. Rajapakse, I. M. Rebeyka, B. McInnes, J. S. Parboosingh, F. P. Bernier, Longer term survival of a child with autosomal recessive cutis laxa due to a mutation in FBLN4. *Am. J. Med. Genet. A* **161**, 1148–1153 (2013).
10. D. R. Berk, D. D. Bentley, S. J. Bayliss, A. Lind, Z. Urban, Cutis laxa: A review. *J. Am. Acad. Dermatol.* **66**, 842.e1–842.e17 (2012).
11. Z. Urban, E. C. Davis, Cutis laxa: Intersection of elastic fiber biogenesis, TGFβ signaling, the secretory pathway and metabolism. *Matrix Biol.* **33**, 16–22 (2014).
12. N. Kobayashi, G. Kostka, J. H. O. Garbe, D. R. Keene, H. P. Bächinger, F.-G. Hanisch, D. Markova, T. Tsuda, R. Timpl, M.-L. Chu, T. Sasaki, A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization. *J. Biol. Chem.* **282**, 11805–11816 (2007).
13. C. L. Papke, H. Yanagisawa, Fibulin-4 and fibulin-5 in elastogenesis and beyond: Insights from mouse and human studies. *Matrix Biol.* **37**, 142–149 (2014).
14. R. Timpl, T. Sasaki, G. Kostka, M.-L. Chu, Fibulins: A versatile family of extracellular matrix proteins. *Nat. Rev. Mol. Cell Biol.* **4**, 479–489 (2003).



15. R. Giltay, R. Timpl, G. Kostka, Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4. *Matrix Biol.* **18**, 469–480 (1999).
16. P. J. McLaughlin, Q. Chen, M. Horiguchi, B. C. Starcher, J. B. Stanton, T. J. Broekelmann, A. D. Marmorstein, B. McKay, R. Mecham, T. Nakamura, L. Y. Marmorstein, Targeted disruption of fibulin-4 abolishes elastogenesis and causes perinatal lethality in mice. *Mol. Cell. Biol.* **26**, 1700–1709 (2006).
17. K. Hanada, M. Vermeij, G. A. Garinis, M. C. de Waard, M. G. S. Kunen, L. Myers, A. Maas, D. J. Duncker, C. Meijers, H. C. Dietz, R. Kanaar, J. Essers, Perturbations of vascular homeostasis and aortic valve abnormalities in fibulin-4 deficient mice. *Circ. Res.* **100**, 738–746 (2007).
18. M. Horiguchi, T. Inoue, T. Ohbayashi, M. Hirai, K. Noda, L. Y. Marmorstein, D. Yabe, K. Takagi, T. O. Akama, T. Kita, T. Kimura, T. Nakamura, Fibulin-4 conducts proper elastogenesis via interaction with cross-linking enzyme lysyl oxidase. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 19029–19034 (2009).
19. J. Huang, E. C. Davis, S. L. Chapman, M. Budatha, L. Y. Marmorstein, R. A. Word, H. Yanagisawa, Fibulin-4 deficiency results in ascending aortic aneurysms: A potential link between abnormal smooth muscle cell phenotype and aneurysm progression. *Circ. Res.* **106**, 583–592 (2010).
20. J. Huang, Y. Yamashiro, C. L. Papke, Y. Ikeda, Y. Lin, M. Patel, T. Inagami, V. P. Le, J. E. Wagenseil, H. Yanagisawa, Angiotensin-converting enzyme-induced activation of local angiotensin signaling is required for ascending aortic aneurysms in fibulin-4-deficient mice. *Sci. Transl. Med.* **5**, 183ra58 (2013).
21. E. Moltzer, L. te Riet, S. M. A. Swagemakers, P. M. van Heijningen, M. Vermeij, R. van Veghel, A. M. Bouhuizen, J. H. M. van Esch, S. Lankhorst, N. W. M. Rammath, M. C. de Waard, D. J. Duncker, P. J. van der Spek, E. V. Rouwet, A. H. J. Danser, J. Essers, Impaired vascular contractility and aortic wall degeneration in fibulin-4 deficient mice: Effect of angiotensin II type 1 (AT<sub>1</sub>) receptor blockade. *PLOS ONE* **6**, e23411 (2011).
22. M. Hirai, T. Ohbayashi, M. Horiguchi, K. Okawa, A. Hagiwara, K. R. Chien, T. Kita, T. Nakamura, Fibulin-5/DANCE has an elastogenic organizer activity that is abrogated by proteolytic cleavage in vivo. *J. Cell Biol.* **176**, 1061–1071 (2007).
23. I. K. Hornstra, S. Birge, B. Starcher, A. J. Bailey, R. P. Mecham, S. D. Shapiro, Lysyl oxidase is required for vascular and diaphragmatic development in mice. *J. Biol. Chem.* **278**, 14387–14393 (2003).
24. J. M. Maki, R. Sormunen, S. Lippo, R. Kaarteenaho-Wiik, R. Soininen, J. Myllyharju, Lysyl oxidase is essential for normal development and function of the respiratory system and for the integrity of elastic and collagen fibers in various tissues. *Am. J. Pathol.* **167**, 927–936 (2005).
25. O. Igoucheva, V. Alexeev, C. M. Halabi, S. M. Adams, I. Stoilov, T. Sasaki, M. Arita, A. Donahue, R. P. Mecham, D. E. Birk, M.-L. Chu, Fibulin-4 E57K knock-in mice recapitulate cutaneous, vascular and skeletal defects of recessive cutis laxa 1B with both elastic fiber and collagen fibril abnormalities. *J. Biol. Chem.* **290**, 21443–21459 (2015).
26. M. W. Majesky, Developmental basis of vascular smooth muscle diversity. *Arterioscler. Thromb. Vasc. Biol.* **27**, 1248–1258 (2007).
27. G. Faury, M. Pezet, R. H. Knutsen, W. A. Boyle, S. P. Heximer, S. E. McLean, R. K. Minkes, K. J. Blumer, A. Kovacs, D. P. Kelly, D. Y. Li, B. Starcher, R. P. Mecham, Developmental adaptation of the mouse cardiovascular system to elastin haploinsufficiency. *J. Clin. Invest.* **112**, 1419–1428 (2003).
28. D. Y. Li, B. Brooke, E. C. Davis, R. P. Mecham, L. K. Sorensen, B. B. Boak, E. Eichwald, M. T. Keating, Elastin is an essential determinant of arterial morphogenesis. *Nature* **393**, 276–280 (1998).
29. D. Y. Li, G. Faury, D. G. Taylor, E. C. Davis, W. A. Boyle, R. P. Mecham, P. Stenzel, B. Boak, M. T. Keating, Novel arterial pathology in mice and humans hemizygous for elastin. *J. Clin. Invest.* **102**, 1783–1787 (1998).
30. T. Nakamura, P. R. Lozano, Y. Ikeda, Y. Iwanaga, A. Hinek, S. Minamisawa, C.-F. Cheng, K. Kobuke, N. Dalton, Y. Takada, K. Tashiro, J. Ross Jr., T. Honjo, K. R. Chien, Fibulin-5/DANCE is essential for elastogenesis in vivo. *Nature* **415**, 171–175 (2002).
31. H. Yanagisawa, E. C. Davis, B. C. Starcher, T. Ouchi, M. Yanagisawa, J. A. Richardson, E. N. Olson, Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo. *Nature* **415**, 168–171 (2002).
32. E. M. Gallo, D. C. Loch, J. P. Habashi, J. F. Calderon, Y. Chen, D. Bedja, C. van Erp, E. E. Gerber, S. J. Parker, K. Sauls, D. P. Judge, S. K. Cooke, M. E. Lindsay, R. Rouf, L. Myers, C. M. ap Rhys, K. C. Kent, R. A. Norris, D. L. Huso, H. C. Dietz, Angiotensin II-dependent TGF- $\beta$  signaling contributes to Loews-Dietz syndrome vascular pathogenesis. *J. Clin. Invest.* **124**, 448–460 (2014).
33. T. M. Holm, J. P. Habashi, J. J. Doyle, D. Bedja, Y. Chen, C. van Erp, M. E. Lindsay, D. Kim, F. Schoenhoff, R. D. Cohn, B. L. Loews, C. J. Thomas, S. Patnaik, J. J. Marugan, D. P. Judge, H. C. Dietz, Noncanonical TGF $\beta$  signaling contributes to aortic aneurysm progression in Marfan syndrome mice. *Science* **332**, 358–361 (2011).
34. N. W. M. Rammath, L. J. A. C. Hawinkels, P. M. van Heijningen, L. te Riet, M. Pauwe, M. Vermeij, A. H. J. Danser, R. Kanaar, P. ten Dijke, J. Essers, Fibulin-4 deficiency increases TGF- $\beta$  signalling in aortic smooth muscle cells due to elevated TGF- $\beta$ 2 levels. *Sci. Rep.* **5**, 16872 (2015).
35. C. L. Papke, J. Tsunozumi, L.-J. Ringuette, H. Nagaoka, M. Terajima, Y. Yamashiro, G. Urquhart, M. Yamauchi, E. C. Davis, H. Yanagisawa, Loss of fibulin-4 disrupts collagen synthesis and maturation: Implications for pathology resulting from *EFEMP2* mutations. *Hum. Mol. Genet.* **24**, 5867–5879 (2015).
36. H. Sugitani, E. Hirano, R. H. Knutsen, A. Shifren, J. E. Wagenseil, C. Ciliberto, B. A. Kozel, Z. Urban, E. C. Davis, T. J. Broekelmann, R. P. Mecham, Alternative splicing and tissue-specific elastin misassembly act as biological modifiers of human elastin gene frameshift mutations associated with dominant cutis laxa. *J. Biol. Chem.* **287**, 22055–22067 (2012).
37. G. M. Clinton, C. Rougeot, J. Derancourt, P. Roger, A. Defrenne, S. Godyna, W. S. Argraves, H. Rochefort, Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 316–320 (1996).
38. T. Nakamura, P. Ruiz-Lozano, V. Lindner, D. Yabe, M. Taniwaki, Y. Furukawa, K. Kobuke, K. Tashiro, Z. Lu, N. L. Andon, R. Schaub, A. Matsumori, S. Sasayama, K. R. Chien, T. Honjo, DANCE, a novel secreted RGD protein expressed in developing, atherosclerotic, and balloon-injured arteries. *J. Biol. Chem.* **274**, 22476–22483 (1999).
39. M. Pfaff, T. Sasaki, K. Tangemann, M.-L. Chu, R. Timpl, Integrin-binding and cell-adhesion studies of fibulins reveal a particular affinity for  $\alpha$ IIb $\beta$ 3. *Exp. Cell Res.* **219**, 87–92 (1995).
40. J. Qing, V. M. Maher, H. Tran, W. S. Argraves, R. W. Dunstan, J. J. McCormick, Suppression of anchorage-independent growth and matrigel invasion and delayed tumor formation by elevated expression of fibulin-1D in human fibrosarcoma-derived cell lines. *Oncogene* **15**, 2159–2168 (1997).
41. W. P. Schiemann, G. C. Blobe, D. E. Kalume, A. Pandey, H. F. Lodish, Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor- $\beta$  and affects protein kinase cascades. *J. Biol. Chem.* **277**, 27367–27377 (2002).
42. C. M. Halabi, T. J. Broekelmann, R. H. Knutsen, L. Ye, R. P. Mecham, B. A. Kozel, Chronic antihypertensive treatment improves pulse pressure but not large artery mechanics in a mouse model of congenital vascular stiffness. *Am. J. Physiol. Heart Circ. Physiol.* **309**, H1008–H1016 (2015).
43. B. Starcher, A ninhydrin-based assay to quantitate the total protein content of tissue samples. *Anal. Biochem.* **292**, 125–129 (2001).
44. G. K. Reddy, C. S. Enwemeka, A simplified method for the analysis of hydroxyproline in biological tissues. *Clin. Biochem.* **29**, 225–229 (1996).
45. Z. Gunja-Smith, An enzyme-linked immunosorbent assay to quantitate the elastin crosslink desmosine in tissue and urine samples. *Anal. Biochem.* **147**, 258–264 (1985).

**Acknowledgments:** We thank T. Hall for administrative assistance. We also thank B. Coleman and M. Scott from the Elvie L. Taylor Histology Core Facility for paraffin embedding, sectioning, and performing von Kossa staining of vessel samples; M. Levy and R. Roth from the Washington University Center for Cellular Imaging for processing and thin sectioning samples for transmission electron microscopy; and A. Kovacs from the Mouse Cardiovascular Phenotyping Core for performing and analyzing mouse echocardiograms. **Funding:** C.M.H. is a Scholar of the Child Health Research Center at Washington University School of Medicine (NIH K12-HD076224). C.M.H. also received support from the NIH (training grant T32-HD043010-11) and the Mallinckrodt Foundation Physician-Scientist Training Program Fellow support. V.S.L. received support from the NIH (training grants T32-EB18266 and T32-HL125241). This work was funded by NIH grants R01-HL53325 and R01-HL105314 to R.P.M. Funding for electron microscopy was provided by the Children's Discovery Institute of Washington University and St. Louis Children's Hospital. **Author contributions:** C.M.H. and R.P.M. conceptualized and designed the research; C.M.H., T.J.B., M.L., and V.S.L. performed experiments and analyzed data; C.M.H., T.J.B., M.L., V.S.L., and R.P.M. interpreted results of experiments; C.M.H. prepared figures and drafted the manuscript; C.M.H. and R.P.M. edited and revised the manuscript; and C.M.H., T.J.B., M.L., V.S.L., M.-L.C., and R.P.M. approved the final version of the manuscript. **Competing interests:** The authors declare that they have no competing interests. **Data and materials availability:** *Fbln4*<sup>E57K/E57K</sup> mice must be obtained through a material transfer agreement. They are also available for purchase from the Jackson Laboratory. Readers may purchase the *Fbln4*(E57K) mice from the Jackson Laboratory website at [www.jax.org/strain/027945](http://www.jax.org/strain/027945). All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Submitted 14 October 2016

Accepted 28 February 2017

Published 3 May 2017

10.1126/sciadv.1602532

**Citation:** C. M. Halabi, T. J. Broekelmann, M. Lin, V. S. Lee, M.-L. Chu, R. P. Mecham, Fibulin-4 is essential for maintaining arterial wall integrity in conduit but not muscular arteries. *Sci. Adv.* **3**, e1602532 (2017).

## Fibulin-4 is essential for maintaining arterial wall integrity in conduit but not muscular arteries

Carmen M. Halabi, Thomas J. Broekelmann, Michelle Lin, Vivian S. Lee, Mon-Li Chu and Robert P. Mecham

*Sci Adv* **3** (5), e1602532.

DOI: 10.1126/sciadv.1602532

### ARTICLE TOOLS

<http://advances.sciencemag.org/content/3/5/e1602532>

### SUPPLEMENTARY MATERIALS

<http://advances.sciencemag.org/content/suppl/2017/05/01/3.5.e1602532.DC1>

### REFERENCES

This article cites 45 articles, 16 of which you can access for free  
<http://advances.sciencemag.org/content/3/5/e1602532#BIBL>

### PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)

---

*Science Advances* (ISSN 2375-2548) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. 2017 © The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. The title *Science Advances* is a registered trademark of AAAS.